8.240CAD+0.61%Mkt Cap: 809.00M CADP/E: 137.33Last update: 2026-06-01
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refr…
Industry Peers
Drug Manufacturers - Specialty & Generic150.78BSEKP/E 166.4
58.93BTRY—
56.89BEURP/E 22.4
32.78BPLNP/E 21.4
23.20BUSDP/E 20.2
18.39BUSD—
16.21BUSDP/E 24.8
13.00BTRY—
Indicators:|
Key Statistics
Company
Market Cap809.00M CAD
Enterprise Value730.68M CAD
Revenue (TTM)510.45M CAD
Gross Profit200.23M CAD
Net Income (TTM)-5.37M CAD
Revenue/Share5.142 CAD
Last Price8.240 CAD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees830
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)137.33
P/E (Forward)30.33
PEG—
EV/EBITDA10.42
EV/Revenue1.43
P/S1.58
P/B1.02
EPS (TTM)0.06
EPS (Forward)0.27
52W Range
5.66080% of range8.900
52W High8.900 CAD
52W Low5.660 CAD
Profitability
Gross Margin44.49%
Oper. Margin7.13%
EBITDA Margin13.74%
Profit Margin-1.19%
ROE-0.70%
ROA-0.51%
Growth
Revenue Growth68.50%
Earnings Growth550.00%
Cash Flow & Leverage
Operating CF68.96M CAD
CapEx (TTM)33.69M CAD
FCF Margin13.01%
FCF Yield8.21%
Net Debt-73.41M CAD
Net Debt/EBITDA-1.05
Balance Sheet
Debt/Equity0.10
Current Ratio2.32
Quick Ratio1.56
Book Value/Sh8.013 CAD
Cash/Share1.458 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)9.829 CAD
Target Range9.000 CAD – 12.00 CAD
# Analysts7
Ownership
Shares Out.98.18M
Float60.24M
Insiders46.95%
Institutions20.06%
Short Interest
Short Ratio20.0d
Short % Out.1.84%
Shares Short1.86M
Short (prev mo.)1.91M
Technical
SMA 507.696 (+7.1%)
SMA 2006.482 (+27.1%)
Beta0.04
S&P 52W Chg27.70%
Avg Vol (30d)85.60K
Avg Vol (10d)68.56K
Technical Indicators
RSI (14)55.2
MACD0.1510
MACD Signal0.2220
MACD Hist.-0.0710
BB Upper8.973 CAD
BB Middle8.194 CAD
BB Lower7.415 CAD
BB Width19.01%
ATR (14)0.2611 CAD
Vol Ratio (20d)1.47x